United Stateshaldatherapeutics.com
Halda Therapeutics is a biotechnology company focused on discovering and developing small‑molecule, targeted therapies for cancer. The company’s approach centers on Regulated Induced Proximity Targeting Chimeras (RIPTACs), a class of bifunctional molecules designed to bring specific proteins into proximity within cancer cells to trigger selective cell killing.
Halda applies medicinal chemistry and structure‑guided design to create orally administered candidates intended to address solid tumors and overcome treatment resistance. Its pipeline is built around induced‑proximity mechanisms with the goal of expanding precision oncology options, and the underlying platform may enable future applications beyond oncology.
None yet. When a new project in the record names Halda as owner, partner or investor, it shows here.
Phase 1 data show 75% imaging response and deep PSA declines at 50 mg; most adverse events were mild–moderate and 50 mg will advance to Phase 2.
New clinical results include first-in-human data for oral RIPTAC JNJ-6143 in mCRPC, late-breaking PROTEUS Phase 3 prostate results, and expanded RYBREVANT FASPRO datasets across lung and head & neck cancers.
The acquisition adds a novel cancer therapy platform and pipeline, impacting earnings in 2025-2026.
The acquisition includes Halda's RIPTAC platform and prostate cancer therapy, HLD-0915, aiming to enhance Johnson & Johnson's oncology pipeline and develop new targeted therapies.
